Oxford BioTherapeutics has partnered with Roche in a multi-year collaboration to advance novel oncology targets, with financial terms that include up to $36 million in upfront payments and potential milestone payments exceeding $1 billion.

Target Information

Oxford BioTherapeutics (OBT) is a clinical-stage oncology company dedicated to developing innovative therapies that address significant unmet needs in cancer treatment. The company specializes in antibody-based therapies, including Bispecific Antibodies and Antibody-Drug Conjugates (ADCs). OBT has launched the enhanced OGAP®-Verify discovery platform, which increases sensitivity in target selection, thus aiding in the discovery and validation of new oncology targets that could be pivotal for drug development.

With an open commitment to advancing the forefront of cancer therapy, OBT has three ongoing clinical programs in the U.S. and Europe that utilize the OGAP capabilities. Its lead clinical program, OBT076, is currently in expansion within a U.S. clinical trial focused on patients with advanced solid tumors, particularly those where CD205 is overexpressed. The company’s innovative approach to discovering and validating human targets provides a solid scientific underpinning for its pipeline.

Industry Overview

The oncology industry in the UK has shown significant growth as advancements in treatment and diagnostics continue to emerge. With increasing incidences of cancer requiring innovative therapies, variou